1. Expanding the Horizons in Hereditary Angioedema

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Hereditary Angioedema Due to C1-INH Deficiency

5. Manifestations of HAE

6. Triggers for HAE Attacks

7. Individualizing Treatment

8. Individualizing Treatment (cont)

9. Short-Term and Preprocedural Prophylaxis

10. Who Is a Candidate for Long-Term Prophylaxis?

11. Long-Term Prophylaxis

12. Long-Term Prophylaxis With Androgens

13. Long-Term Prophylaxis With Antifibrinolytic Agents

14. Long-Term Prophylaxis Plasma-Derived C1-INH Concentrate: 1000 Units Twice Weekly

15. Long-Term Prophylaxis With Intravenously Infused C1-INH

16. Physician Survey on Current Trends in Long-Term HAE Prophylaxis Use

17. Frequency of Peripheral Vein Difficulties During the Past 6 Months

18. COMPACT Study Number of HAE Attacks per Month

19. COMPACT Study Use of Rescue Medication

20. Long-Term Prophylaxis Subcutaneously Injected C1-INH

21. Emerging Agents for Prophylactic Use

22. Ongoing Preclinical Research

23. A Comprehensive, Individualized Management Plan

24. Individualized, Patient-Centric Plan for Prophylaxis

25. Patient-Caregiver Education

26. Patients Should Have an Action Plan for Attacks

27. Concluding Remarks

28. Abbreviations